Ä¢¹½ÊÓƵAPP

John Mendlein, Ph.D., joined Flagship as executive partner in February 2019. A longtime member of Flagship’s broader ecosystem of companies, John is an experienced biotech leader and has served in numerous executive and board roles. At Flagship, John contributes to Flagship’s strategic and operational objectives, including the origination of new Flagship Labs companies and growth companies. He also serves on the boards of Flagship’s companies and works with portfolio company CEOs and their teams to achieve the best attainable value for each organization.

Throughout his multi-decade career in biotech, John has helped start and lead numerous innovative life sciences companies with product platforms. Prior to joining Flagship, John served as president of corporate and product strategy at Moderna Therapeutics (NASDAQ: MRNA), a Ä¢¹½ÊÓƵAPP company. John was also a member of Moderna’s board of directors from 2012-2018.

He has also held leadership roles at multiple additional biotech platform enterprises. John was chief knowledge officer and general counsel at Aurora Biosciences (acquired by Vertex Pharmaceuticals) where he also served as a board member; CEO of Adnexus Therapeutics, a Flagship company (acquired by BMS); executive chairman, founder, and interim CEO of Fate Therapeutics (a publicly-traded (FATE) immuno-oncology cell therapy platform company); and executive chairman and CEO of Affinium Pharmaceuticals (acquired by Debiopharm Group).

John is co-author or co-inventor of over 210 publications and published patents. He has served on the boards of the Biotechnology Innovation Organization (BIO), as well as Flagship’s companies: Moderna (NASDAQ: MRNA), Axcella Therapeutics and Editas Medicine (NASDAQ: EDIT). John currently serves on the boards of Flagship companies Omega Therapeutics (OMEGA), Empress, and Profound, and is Executive Chairman of Sail Biomedicines and Versalius.

John holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, San Francisco, and a B.S. in biology from the University of Miami.